- More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing ...

Labroots invites you to the 4th Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...

Researchers have made an important step forward toward a long-desired goal: using the gene-editing technology CRISPR to treat cancer. In a study published in Nature, scientists recruited 16 people who ...

When Victoria Gray was still a baby, she started howling so inconsolably during a bath that she was rushed to the emergency room. The diagnosis was sickle-cell disease, a genetic condition that causes ...

We recently compiled a list of the 10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) ...

If you're looking to add some growth to your portfolio, you may find it in biotech stocks. Two in particular offer investors a terrific opportunity right now. That's because both of them are in the ...

Nobel Prize winner Emmanuelle Charpentier, Ph.D., and two universities have officially appealed in a dispute over certain patents for CRISPR gene editing, a long-running challenge that could have wide ...

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...

Five years on from being the first person in the world to receive intravenous CRISPR treatment, Westmeath woman describes the clinical trial she participated in as ‘life-changing’ ...